Stephen V Liu, MD Profile picture
Sep 19, 2020 15 tweets 15 min read Read on X
#ESMO20 Discussion of the phase III CROWN trial results (planned interim analysis): lorlatinib vs crizotinib in treatment naive #ALK #NSCLC by @bensolomon1 - potentially practice changing data in an important subset of lung cancer. #LCSM @OncoAlert Image
#ESMO20 #ALK fusion positive NSCLC is an important subset where we have very potent and active agents with PFS measured in years - but always room for improvement. #LCSM @OncoAlert Image
#ESMO20 Study design for CROWN shown here. Standard 1:1 randomization to lorlatinib 100mg qday vs crizotinib 250mg bid, stratified by Asian vs not and presence or absence of brain metastases. Primary endpoint was PFS by BICR. #LCSM @OncoAlert ImageImageImage
#ESMO20 Baseline characteristics show that 26% of patients had brain metastases (only 6% with prior radiation) and by central MRI review. #LCSM @OncoAlert Image
Wow.

PFS by BICR HR 0.28 substantially better (across trials) than we saw with alectinib or brigatinib (0.47-0.49). 12 month PFS rate 78% with lorlatinib vs 39% with crizotinib. #LCSM #ESMO20 @OncoAlert Image
#ESMO20 Here we see investigator assessed PFS HR was 0.21 favoring lorlatinib over crizotinib as 1L therapy for #ALK NSCLC. #LCSM @OncoAlert Image
#ESMO20 Benefit seen across all subgroups with a better HR in patients with brain metastases (HR 0.20) but still impressive in those without (0.32) but overall, benefit seen across the board. #LCSM @OncoAlert Image
#ESMO20 ORR 76% with lorlatinib vs 58% with crizotinib. Both work quickly (median time to response 1.8m) but duration of response not reached for lorlatinib (11m for crizotinib). #LCSM @OncoAlert Image
#ESMO20 Lorlatinib has greater CNS penetrance than other ALK TKIs and we see impressive CNS results in CROWN. Intracranial response rate in those with measurable disease was 82% with lorlatinib - 71% were complete responses! #LCSM @OncoAlert Image
#ESMO20 The intracranial time to progression (BICR, MRI) not reached but the HR was 0.07 (!!!) and that lorlatinib line is about as flat as can be. #LCSM @OncoAlert Image
#LCSM Very early look at OS - this will be critical to follow. As resistance mechanisms vary by agent used, we don't know much about resistance to first line lorlatinib and over time, analysis of PFS2/PFS3 may be interesting. #LCSM @OncoAlert Image
#ESMO20 A big consideration is safety with lorlatinib. Note that 72% had grade 3/4 AEs and 5% with fatal AE. Dose interruption seen in about half of patients. AE leading to permanent discontinuation in only 7%. #LCSM @OncoAlert Image
#ESMO20 The tornado plot shows some unique toxicities with lorlatinib including hyperlipidemia. Of utmost concern to me are the neurocognitive effects - noted in ~20% of patients. I feel these can be underreported, however, if recognized, they respond to dose reduction. #LCSM Image
#ESMO20 Importantly, lorlatinib associated with better QoL scores - glad these are being captured. Image
#ESMO20 We all expected lorlatinib to beat crizotinib but a HR of 0.28 certainly surpassed my expectations (like an ALK-DAURA). Seems like a new SOC but some hesitation given impact on sequencing and, most importantly, toxicity - esp neurocognitive impact. #LCSM @OncoAlert Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Stephen V Liu, MD

Stephen V Liu, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @StephenVLiu

Apr 23, 2023
Dr. Shun Lu presents interim results from the perioperative NEOTORCH study at the #ASCOPlenarySeries. Randomized pts with resectable stage II/III NSCLC to perioperative chemotherapy with toripalimab (anti-PD1) vs placebo. Another entry in the perioperative space? #LCSM Image
Includes resectable stage II/III (AJCC v8), EGFR/ALK wild type NSCLC. Pts receive 3 cycles of neoadjuvant chemotherapy + toripalimab vs placebo then surgery then 1 more cycle of adjuvant chemo (+tori/pbo) then 13 doses of maintenance toripalimab vs placebo. #ASCOPlenarySeries Image
First interim EFS analysis only for stage III. Includes 404 pts - but 926 screened. Would be interesting to see specific eligibility criteria not met in screening process. Reminder of how selected trial populations are and value of future real-world analyses. #ASCOPlenarySeries ImageImage
Read 11 tweets
Apr 16, 2023
Impressive data from #AEGEAN at #AACR23 from Dr. John Heymach and colleagues. This is the first of several phase III peri-operative IO studies in resectable NSCLC combining neoadjuvant chemo-immunotherapy followed by adjuvant immunotherapy. Image
Included stage IIA-IIIB (AJCC v8) with no EGFR/ALK & excluded pts who would require pneumonectomy. Large study with n=801 (CM816 was n=358). Pts received 4 cycles (not 3) of platinum-based chemo with durvalumab (anti-PDL1) or placebo, then surgery, then durvalumab / placebo x 1y. Image
Almost 75% received carboplatin over cisplatin. Global study; fairly even PDL1 distribution. 80% of pts went to surgery, 78% completed resection (90-95% of those were R0). Overall, 66% of pts began adjuvant phase (but 90% of those who had an R0 resection had adjuvant therapy). ImageImageImage
Read 9 tweets
Dec 8, 2022
There is a lot to consider in this first-line study of the #KRAS G12C inhibitor adagrasib plus pembrolizumab from #ESMOImmuno22. Some pleasant surprises in terms of safety. Definitely encouraging but need to see a bit more to be sold on this strategy. 🤔 #LCSM Image
We're looking for synergy with the two agents - more than an additive effect. Reason to believe there will be based on preclinical data showing the effect on T-cell infiltration from #KRAS inhibition. Similar to what has been shown with MEK inhibition. #ESMOImmuno22 Image
The first-line dataset includes the phase Ib KRYSTAL-1 and the phase II KRYSTAL-7. In KRYSTAL-1 (n=7), 4/7 had a response and all were durable (>9m). G3 TRAEs in 4 pts (lipase elevation, LFTs, muscular pain, pneumothorax). #ESMOImmuno22 ImageImage
Read 10 tweets
Sep 19, 2022
Dr. @ZPiotrowskaMD presents initial results from the ELIOS trial at #ESMO22 - molecular profiling of #EGFR mutant NSCLC after progression on 1L osimertinib. ImageImage
In this study of highly motivated pts at esteemed sites, evaluable paired biopsy at PD only available in 46/115 pts (40%). Interestingly, 75 pts (65%) had paired biopsy but 27 failed NGS (23%). Speaks somewhat to the real world feasibility of a repeat biopsy approach. #ESMO22 Image
Common co-mutations at baseline included TP53, EGFR amp, and CDKN2A loss. Acquired alterations included MET amp, EGFR C797S, ALK fusion, NKX2-1 amp. Mostly mutually exclusive. #ESMO22 ImageImageImage
Read 5 tweets
Sep 11, 2022
Dr. Silvia Novello presents 5y update on KEYNOTE 407 (platinum plus tax and +/- pembrolizumab for 1L squamous NSCLC #ESMO22
With longer follow up, OS favors pembrolizumab arm with mOS 17.2 vs 11.6m (OS HR 0.71) in squamous NSCLC. 5y OS rate 18.4% vs 9.7%. PFS benefit (HR 0.62) and higher RR across PDL1 strata. #ESMO22
For patients who complete 2y of pembrolizumab, 3y OS rate (after completing 2y pembro) was 70% - though not all of those patients are cured (44% were alive without PD or subsequent therapy). #ESMO22
Read 4 tweets
Sep 11, 2022
Dr. @marinagarassino presents 5-year efficacy and safety update of KEYNOTE-189 (1L carboplatin plus pemetrexed +- pembrolizumab in non-squamous NSCLC) #ESMO22
KEYNOTE 189 is our SOC and has shown a consistent benefit including improving OS even with a crossover rate of 57%. #ESMO22
KEYNOTE 189 shows sustained OS benefit with longer follow up and a 5y OS rate of 18.4% with an OS HR of 0.60. Better PFS and OS also observed. Benefit across PDL1 strata. No new safety signals . #ESMO22
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(